Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Study 2 (NCT 00435136) This study re-randomized 177 HIV-infected patients with lipodystrophy who completed EGRIFTA treatment in the Main Phase to receive either a 2 mg dose of EGRIFTA (1 mg/vial formulation) (N=92) or placebo (N=85) for an additional 26-week duration (1:1 randomization ratio)
Our results suggest that C
Just be sure to patch test beforehand
Product Features: Reconstitution Solution per bottle High Purity Formula Manufactured in the USA Premium pharmaceutical-grade packaging Securely sealed for freshness and stability Research Use Only At Core Power Peptides, we are committed to providing premium laboratory and research products trusted by researchers and professionals worldwide
US$ 29.18
US$ 28.27
US$ 20.22
US$ 21.45
US$ 23.33
US$ 25.82
US$ 20.00
